Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not been demon...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Allergy Asthma Clin Immunol
Hauptverfasser: Mukherjee, Manali, Kjarsgaard, Melanie, Radford, Katherine, Huang, Chynna, Leigh, Richard, Dorscheid, Delbert R., Lemiere, Catherine, Boulet, Louis-Philippe, Waserman, Susan, Martin, James, Nair, Parameswaran
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2019
Schlagworte:
Letter to the Editor
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6448265/
https://ncbi.nlm.nih.gov/pubmed/30988677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-019-0337-2
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge